Lilly and Incyte Announce Patients Treated with Baricitinib Demonstrated Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Compared with Methotrexate
INDIANAPOLIS, Nov. 9, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce detailed data from the pivotal phase 3 RA-BEGIN study, which show investigational baricitinib alone and in combination were superior to methotrexate monoth...
Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis
INDIANAPOLIS, Sept. 29, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with mod...
Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries
INDIANAPOLIS and INGELHEIM, Germany, Oct. 29, 2014 /PRNewswire/ -- In a move that will strengthen their alliance by enhancing efficiencies and enabling greater focus on product launches, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are changing the operational and financial structur...
Lilly and Alzheimer's Disease International Partner to Address Barriers that Impact the Accurate and Timely Diagnosis of Alzheimer's Disease
-- New educational resources to help patients and caregivers communicate vital information with physicians are released as global leaders meet to discuss the global burden of Alzheimer's disease INDIANAPOLIS, June 12, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Alzheimer's Disease Int...
Lilly Releases Report on Corporate Responsibility Efforts
-- Company communicates progress on numerous indicators of economic, environmental, and social performance INDIANAPOLIS, Dec. 6, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has released its 2012-13 Corporate Responsibility Report( http://www.lilly.com/Documents/Lilly_2012_2013_CRreport.p...
Amyvid (Florbetapir (18F)) Solution for Injection Approved in European Union for Use in Patients with Cognitive Impairment Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Impairment
Amyvid is the first and only PET imaging agent approved to measure beta-amyloid neuritic plaque density in the living brain INDIANAPOLIS, Jan. 16, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the E...
Lilly Releases Update on Corporate Responsibility Efforts
Company communicates progress on numerous indicators of economic, environmental and social performance INDIANAPOLIS, Dec. 3, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has released its 2011/2012 Corporate Responsibility Update (www.lilly.com/Documents/Lilly_2011_2012_CRupdate.pdf). Th...
European Commission Approves Cialis for the Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia
Cialis becomes the first and only medication approved in the EU for both the signs and symptoms of benign prostatic hyperplasia and erectile dysfunction INDIANAPOLIS, Oct. 30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has approved Cialis(R) ...
ALIMTA(R) Label Update Approved by European Commission to Reflect Significant Overall Survival Benefits for Specific Lung Cancer Patients
INDIANAPOLIS, Oct. 30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has approved an update to the label for ALIMTA(R) (pemetrexed for injection), adding final overall survival data to the continuation maintenance indication for patients with adv...
Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient(R) (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure
Study did not meet primary objective of demonstrating prasugrel superiority over clopidogrel in this patient population INDIANAPOLIS and TOKYO, Aug. 27, 2012 /PRNewswire-Asia/ -- Daiichi Sankyo Company, Limited (TSE: 4568), and Eli Lilly and Company (NYSE: LLY) today announced data from the TRIL...
